TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked.
Two things I would like separated before anyone answers on TB-500 and thymosin beta-4, because they get bundled and then argued about as one thing.
The first is descriptive: what has actually been observed, by whom, and how. The second is causal: why. I am asking about the first only.
TB-500 and thymosin beta-4 is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
Adding a small correction to the TB-500 and thymosin beta-4 summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.
Post #4 is the version of this I will quote in future. One addition.
TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.
Where I part company with post #2, and it is a narrow parting.
Two questions I would want answered before drawing anything from the TB-500 and thymosin beta-4 data above: how were the cases selected, and what happened to the ones that dropped out.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
Adding it in case it saves somebody the afternoon it cost me.
TB-500 and thymosin beta-4: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
I had written a reply contradicting post #9 and deleted it. Here is what survived.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
Coming back to post #13, because the follow-up matters more than the original answer.
Before the thread moves on from TB-500 and thymosin beta-4 — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
Post #13 is right about the mechanism and I think understates the practical bit.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
That is a description of practice, not a recommendation of it.
Adding the boring version of TB-500 and thymosin beta-4, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Adding a source would improve this post and I do not have one to hand.
Building on post #17 rather than restating it.
Where I have landed on TB-500 and thymosin beta-4, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.
TB-500 is a fragment rather than the whole thymosin beta-4 protein, and the two are used interchangeably in product descriptions when they should not be. The fragment is what is generally supplied.
Not the answer, but possibly the question that gets there.
A definition problem is doing most of the work in this TB-500 and thymosin beta-4 discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.
This is the answer, and the reason it is the answer is the more useful part.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What would change my mind about repair peptides: a specific answer — one year on
What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Documentation question rather than a…
|
+9 | 13 | 42k | 19mo |
|
Why the absence of controlled human data on BPC-157 matters more than people admit
Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to know what people…
|
+60 | 66 | 16k | 1d |
|
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about…
|
+50 | 55 | 7.8k | 2d |
|
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold?
The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I would like to…
|
+6 | 10 | 3.1k | 1d |
|
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset
On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. The question about BPC-157 that I actually want…
|
+77 | 84 | 54k | 11mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Sequence verification for an obscure compound: how it is done
Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Asking about sequence verification directly, because I have…
|
+104 | 114 | 10k | 12mo |
|
CJC-1295 with and without DAC: what the modification does
On the subject in the title: CJC-1295 with and without DAC: what the modification does Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a compound…
|
+117 | 123 | 5.6k | 22h |
|
A preprint whose numbers changed substantially at publication
A preprint whose numbers changed substantially at publication — setting out what I have, and where I think it stops being reliable. A preprint question rather than a question about the finding in it. The…
|
+90 | 95 | 21k | 9mo |
|
A widely repeated interaction claim that turns out to be unsupported
On the subject in the title: A widely repeated interaction claim that turns out to be unsupported Working notes rather than a conclusion. I was wrong about widely repeated interaction claim in a thread last…
|
+47 | 51 | 37k | 3mo |
|
Delayed gastric emptying and oral medication absorption: which drugs matter — one year on
On the subject in the title: Delayed gastric emptying and oral medication absorption: which drugs matter — one year on Working notes rather than a conclusion. A follow-up question about Delayed gastric…
|
3 | 16k | 2mo |